Recent developments in the diagnosis of pancreatic neuroendocrine neoplasms

References

• Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–1492. doi: 10.1053/j.gastro.2008.05.047
   PubMed Web of Science ®Google Scholar
• Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471–487. doi: 10.3322/caac.21493
   PubMed Web of Science ®Google Scholar
• Öberg K. Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol. 1994;6(4):441–451. doi: 10.1097/00001622-199407000-00018
   PubMedGoogle Scholar
• Kim DW, Kim HJ, Kim KW, et al. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol. 2015;25(5):1375–1383. doi: 10.1007/s00330-014-3532-z
   PubMed Web of Science ®Google Scholar
• Couvelard A, O’Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92(1):94–101. doi: 10.1038/sj.bjc.6602245
   PubMed Web of Science ®Google Scholar
• Marion–Audibert A, Barel C, Gouysse G, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology. 2003;125(4):1094–1104. doi: 10.1016/S0016-5085(03)01198-3
   PubMed Web of Science ®Google Scholar
• Guilmette JM, Nosé V. Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol. 2019;26(1):13–30. doi: 10.1097/PAP.0000000000000201
   PubMed Web of Science ®Google Scholar
• Frilling A, Modlin IM, Kidd M, et al. Review recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–e21. doi: 10.1016/S1470-2045(13)70362-0
   PubMed Web of Science ®Google Scholar
• Gangi A, Howe JR. The landmark series: neuroendocrine tumor liver metastases. Ann Surg Oncol Springer. 2020;27(9):3270–3280. doi: 10.1245/s10434-020-08787-x
   PubMed Web of Science ®Google Scholar
• Lloyd R, Osamura R, Klopper G, et al. WHO classification of tumours of endocrine organs. 4th. Lyon: IARC; 2017.
   Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi: 10.1111/his.13975
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. doi: 10.1001/jamaoncol.2017.0589
   PubMed Web of Science ®Google Scholar
• Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013;20(9):2815–2821. doi: 10.1245/s10434-013-3005-7
   PubMed Web of Science ®Google Scholar
• Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Dig Dis Sci. 1991;36(7):933–942. doi: 10.1007/BF01297144
   PubMed Web of Science ®Google Scholar
• Hallet J, Law CHL, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–597. doi: 10.1002/cncr.29099
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocri Related Cancer. 2008;15(2):409–427. doi: 10.1677/ERC-07-0221
   PubMed Web of Science ®Google Scholar
• Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860. doi: 10.1016/j.annonc.2020.03.304
   PubMed Web of Science ®Google Scholar
• Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology S Karger AG. 2016;103(2):153–171. doi: 10.1159/000443171
   PubMed Web of Science ®Google Scholar
• Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg. 2016;104(1):34–41. doi: 10.1002/bjs.10312
   PubMed Web of Science ®Google Scholar
• Sandvik OM, Søreide K, Gudlaugsson E, et al. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br J Surg. 2016;103(3):226–232. doi: 10.1002/bjs.10034
   PubMed Web of Science ®Google Scholar
• Pulvirenti A, Javed AA, Michelakos T, et al. Recurring pancreatic neuroendocrine tumor: timing and pattern of recurrence, and current treatment. Annals Of Surgery. 2023;278(5):e1063–e1067. doi: 10.1097/SLA.0000000000005809
   PubMed Web of Science ®Google Scholar
• Genç CG, Jilesen AP, Partelli S, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2018;267(6):1148–1154. doi: 10.1097/SLA.0000000000002123
   PubMed Web of Science ®Google Scholar
• Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656–669. doi: 10.1038/s41574-018-0082-5
   PubMed Web of Science ®Google Scholar
• Hofland J, Falconi M, Christ E, et al. European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. doi: 10.1111/jne.13318
   PubMedGoogle Scholar
• Vinik AI, Woltering EA, Warner RRP, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713–734. doi: 10.1097/MPA.0b013e3181ebaffd
   PubMed Web of Science ®Google Scholar
• Tao M, Yuan C, Xiu D, et al. Analysis of risk factors affecting the prognosis of pancreatic neuroendocrine tumors. Chinese Medical Journal. 2014;127(16):2924–2928. doi: 10.3760/cma.j.issn.0366-6999.20132104
   PubMed Web of Science ®Google Scholar
• Zhuge X, Guo C, Chen Y, et al. The levels of tumor markers in pancreatic neuroendocrine carcinoma and their values in differentiation between pancreatic neuroendocrine carcinoma and pancreatic ductal adenocarcinoma. Pancreas. 2018;47(10):1290–1295. doi: 10.1097/MPA.0000000000001181
   PubMed Web of Science ®Google Scholar
• Smolkova B, Kataki A, Earl J, et al. Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. Crit Rev Oncol Hematol. 2022;180:103865. doi: 10.1016/j.critrevonc.2022.103865
   PubMed Web of Science ®Google Scholar
• Bocchini M, Nicolini F, Severi S, et al. Biomarkers for pancreatic neuroendocrine neoplasms (PanNens) management—an updated review. Front Oncol. 2020;10:831. doi: 10.3389/fonc.2020.00831
   PubMed Web of Science ®Google Scholar
• Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS ONE. 2015;10(4):e0124884. doi: 10.1371/journal.pone.0124884
   PubMed Web of Science ®Google Scholar
• Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17(9):2427–2443. doi: 10.1245/s10434-010-1006-3
   PubMed Web of Science ®Google Scholar
• Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30(1):59–77. doi: 10.1016/j.beem.2016.01.002
   PubMed Web of Science ®Google Scholar
• Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin a levels in man. Eur J Endocrinol. 2004:299–303. doi: 10.1530/eje.0.1500299
   PubMed Web of Science ®Google Scholar
• Sansone A, Lauretta R, Vottari S, et al. Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers (Basel). 2019;11(8):1113. doi: 10.3390/cancers11081113
   PubMed Web of Science ®Google Scholar
• Nguyen M, Li M, Travers A, et al. Role of chromogranin a in the diagnosis and follow-up of neuroendocrine tumors. Pancreas. 2022;51(8):1007–1010. doi: 10.1097/MPA.0000000000002132
   PubMed Web of Science ®Google Scholar
• Andreasi V, Partelli S, Manzoni MF, et al. Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors. J Endocrinol Invest. 2022;45(6):1209–1217. doi: 10.1007/s40618-022-01750-5
   PubMed Web of Science ®Google Scholar
• Fang JM, Li J, Shi J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. WJG. 2022;28(10):1009–1023. doi: 10.3748/wjg.v28.i10.1009
   PubMed Web of Science ®Google Scholar
• Hoej LB, Parkner T, Knudsen CS, et al. A comparison of ree chromogranin a assays in patients with neuroendocrine tumours. JGLD. 2014;23(4):419–424. doi: 10.15403/jgld.2014.1121.234.3ca
   PubMed Web of Science ®Google Scholar
• Pulvirenti A, Rao D, Mcintyre CA, et al. Limited role of chromogranin a as clinical biomarker for pancreatic neuroendocrine tumors. HPB. 2019;21(5):612–618. doi: 10.1016/j.hpb.2018.09.016
   PubMed Web of Science ®Google Scholar
• Massironi S, Conte D, Sciola V, et al. Plasma chromogranin a response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105(9):2072–2078. doi: 10.1038/ajg.2010.154
   PubMed Web of Science ®Google Scholar
• Ma Z-Y, Gong Y-F, Zhuang H-K, et al. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol. 2020;26(19):2305–2322. doi: 10.3748/wjg.v26.i19.2305
   PubMed Web of Science ®Google Scholar
• Andreasi V, Partelli S, Manzoni M, et al. Association between preoperative vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). Pancreatology. 2019;19(1):57–63. doi: 10.1016/j.pan.2018.11.005
   PubMed Web of Science ®Google Scholar
• Corsello A, Di Filippo L, Massironi S, et al. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. PLoS ONE. 2018;13(5):e0196858. doi: 10.1371/journal.pone.0196858
   PubMed Web of Science ®Google Scholar
• Melen-Mucha G, Niedziela A, Mucha S, et al. Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors. Int J Mol Sci. 2012;13(2):1444–1460. doi: 10.3390/ijms13021444
   PubMed Web of Science ®Google Scholar
• Simon T, Riemer P, Jarosch A, et al. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. Genome Med. 2022;14(1):24. doi: 10.1186/s13073-022-01018-w
   PubMed Web of Science ®Google Scholar
• Detjen KM, Rieke S, Deters A, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res. 2010;16(2):420–429. doi: 10.1158/1078-0432.CCR-09-1924
   PubMed Web of Science ®Google Scholar
• Figueroa-Vega N, Díaz Á, Adrados M, et al. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr Relat Cancer. 2010;17(4):897–908. doi: 10.1677/ERC-10-0020
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Dancey G, Hackshaw A, et al. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr Relat Cancer. 2009;16(3):967–976. doi: 10.1677/ERC-09-0089
   PubMed Web of Science ®Google Scholar
• Kidd M, Modlin IM, Drozdov I, et al. A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis. Oncotarget. 2018;9(6):7182–7196. doi: 10.18632/oncotarget.23820
   PubMedGoogle Scholar
• Al-Toubah T, Cives M, Valone T, et al. Sensitivity and specificity of the NETest: a validation study. Neuroendocrinology. 2021;111(6):580–585. doi: 10.1159/000509866
   PubMed Web of Science ®Google Scholar
• Pavel M, Jann H, Prasad V, et al. NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive. Neuroendocrinology. 2017;104(2):170–182. doi: 10.1159/000446025
   PubMed Web of Science ®Google Scholar
• van Treijen MJC, Korse CM, Verbeek WH, et al. NETest: serial liquid biopsies in gastroenteropancreatic NET surveillance. Endocr Connect. 2022;11(10):e220146. doi: 10.1530/EC-22-0146
   PubMed Web of Science ®Google Scholar
• Partelli S, Andreasi V, Muffatti F, et al. Circulating neuroendocrine gene transcripts (NETest): a postoperative strategy for early identification of the efficacy of radical surgery for pancreatic neuroendocrine tumors. Ann Surg Oncol. 2020;27(10):3928–3936. doi: 10.1245/s10434-020-08425-6
   PubMed Web of Science ®Google Scholar
• Malczewska A, Kos-Kudła B, Kidd M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci. 2020;65(1):18–29. doi: 10.1016/j.advms.2019.10.002
   PubMed Web of Science ®Google Scholar
• Öberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31:202–212.
   PubMed Web of Science ®Google Scholar
• Malczewska A, Oberg K, Kos-Kudla B. Netest is superior to chromogranin a in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocr Connect. 2021;10(1):110–123. doi: 10.1530/EC-20-0417
   PubMed Web of Science ®Google Scholar
• Modlin IM, Kidd M, Falconi M, et al. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Ann Oncol. 2021;32(11):1425–1433. doi: 10.1016/j.annonc.2021.08.1746
   PubMed Web of Science ®Google Scholar
• Gleeson FC, Voss JS, Kipp BR, et al. Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. Oncotarget. 2017;8(55):93464–93475. doi: 10.18632/oncotarget.18750
   PubMedGoogle Scholar
• Zakka K, Nagy R, Drusbosky L, et al. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget. 2020;11(19):1749–1757. doi: 10.18632/oncotarget.27588
   PubMedGoogle Scholar
• Panarelli N, Tyryshkin K, Wong JJM, et al. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Endocr Relat Cancer. 2019;26(1):47–57. doi: 10.1530/ERC-18-0244
   PubMed Web of Science ®Google Scholar
• Korotaeva A, Mansorunov D, Apanovich N, et al. MiRNA expression in neuroendocrine neoplasms of frequent localizations. Noncoding RNA. 2021;7(3):38. doi: 10.3390/ncrna7030038
   PubMed Web of Science ®Google Scholar
• Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31(3):365–372. doi: 10.1200/JCO.2012.44.2905
   PubMed Web of Science ®Google Scholar
• Khanna L, Prasad SR, Sunnapwar A, et al. Pancreatic neuroendocrine neo-plasms: 2020 update on pathologic and imaging findings and classification. Radiographics. 2020;40(5):1240–1262. doi: 10.1148/rg.2020200025
   PubMed Web of Science ®Google Scholar
• Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105(3):212–244. doi: 10.1159/000471879
   PubMed Web of Science ®Google Scholar
• Kim C, Byun JH, Hong SM, et al. A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis. Abdom Radiol. 2017;42(12):2835–2842. doi: 10.1007/s00261-017-1212-6
   PubMed Web of Science ®Google Scholar
• Cappelli C, Boggi U, Mazzeo S, et al. Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. Eur Radiol. 2015;25(3):751–759. doi: 10.1007/s00330-014-3485-2
   PubMed Web of Science ®Google Scholar
• Battistella A, Partelli S, Andreasi V, et al. Preoperative assessment of microvessel density in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). Surgery. 2022;172(4):1236–1244. doi: 10.1016/j.surg.2022.06.017.
   PubMed Web of Science ®Google Scholar
• d’Assignies G, Couvelard A, Bahrami S, et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion ct reflects angiogenesis and correlates with prognostic factors 1. Radiology. 2009;250(2):407–416. doi: 10.1148/radiol.2501080291
   PubMed Web of Science ®Google Scholar
• Takumi K, Fukukura Y, Higashi M, et al. Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur J Radiol. 2015;84:1436–1443.
   PubMed Web of Science ®Google Scholar
• Partelli S, Bartsch DK, Capdevila J, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105(3):255–265. doi: 10.1159/000464292
   PubMed Web of Science ®Google Scholar
• Pellegrino F, Granata V, Fusco R, et al. Diagnostic management of gastroenteropancreatic neuroendocrine neoplasms: technique optimization and tips and tricks for radiologists. Tomography. 2023;9(1):217–246. doi: 10.3390/tomography9010018
   PubMed Web of Science ®Google Scholar
• Chiti G, Grazzini G, Cozzi D, et al. Imaging of pancreatic neuroendocrine neoplasms. Int J Environ Res Public Health. 2021;18(17):8895. doi: 10.3390/ijerph18178895
   PubMed Web of Science ®Google Scholar
• d’Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013;268(2):390–399. doi: 10.1148/radiol.13121628.
   PubMed Web of Science ®Google Scholar
• Ronot M, Clift AK, Baum RP, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology. 2018;106(1):74–88. doi: 10.1159/000479293
   PubMed Web of Science ®Google Scholar
• Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23(1):70–78. doi: 10.1200/JCO.2005.01.013
   PubMed Web of Science ®Google Scholar
• Segaran N, Devine C, Wang M, et al. Current update on imaging for pancreatic neuroendocrine neoplasms. World J Clin Oncol. 2021;12(10):897–911. doi: 10.5306/wjco.v12.i10.897
   PubMed Web of Science ®Google Scholar
• Scott AT, Howe JR. Evaluation and management of neuroendocrine tumors of the pancreas. Vol. 99. Surgical Clinics Of North America: W.B. Saunders; 2019. p. 793–814.
   Google Scholar
• Hayoz R, Vietti-Violi N, Duran R, et al. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol. 2020;30(12):6593–6602. doi: 10.1007/s00330-020-06930-6
   PubMed Web of Science ®Google Scholar
• Tirumani SH, Jagannathan JP, Braschi-Amirfarzan M, et al. Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent. Abdom Radiol. 2018;43(9):2329–2339. doi: 10.1007/s00261-018-1496-1
   PubMed Web of Science ®Google Scholar
• Ringe KI, Husarik DB, Sirlin CB, et al. Gadoxetate disodium–enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. Am J Roentgenol. 2010;195(1):13–28. doi: 10.2214/AJR.10.4392
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–577. doi: 10.1148/radiol.2015151169
   PubMed Web of Science ®Google Scholar
• Castellano G, Bonilha L, Li LM, et al. Texture analysis of medical images. Clin Radiol. 2004;59(12):1061–1069. doi: 10.1016/j.crad.2004.07.008
   PubMed Web of Science ®Google Scholar
• Savadjiev P, Chong J, Dohan A, et al. Image-based biomarkers for solid tumor quantification. Eur Radiol. 2019;29(10):5431–5440. doi: 10.1007/s00330-019-06169-w
   PubMed Web of Science ®Google Scholar
• Guo C, Ren S, Chen X, et al. Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance. Cancer Manag Res. 2019;11:1933–1944. doi: 10.2147/CMAR.S195376
   PubMed Web of Science ®Google Scholar
• Li X, Zhu H, Qian X, et al. MRI texture analysis for differentiating nonfunctional pancreatic neuroendocrine neoplasms from solid pseudopapillary neoplasms of the pancreas. Acad Radiol. 2020;27(6):815–823. doi: 10.1016/j.acra.2019.07.012
   PubMed Web of Science ®Google Scholar
• De Robertis R, Maris B, Cardobi N, et al. Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? Eur Radiol. 2018;28(6):2582–2591. doi: 10.1007/s00330-017-5236-7
   PubMed Web of Science ®Google Scholar
• Loi S, Mori M, Benedetti G, et al. Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms. Phys Med. 2020;76:125–133. doi: 10.1016/j.ejmp.2020.06.025
   PubMed Web of Science ®Google Scholar
• Mori M, Palumbo D, Muffatti F, et al. Prediction of the characteristics of aggressiveness of pancreatic neuroendocrine neoplasms (PanNens) based on CT radiomic features. Eur Radiol. 2023;33(6):4412–4421. doi: 10.1007/s00330-022-09351-9.
   PubMed Web of Science ®Google Scholar
• Mori M, Benedetti G, Partelli S, et al. Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. Phys Med. 2019;57:41–46. doi: 10.1016/j.ejmp.2018.12.005
   PubMed Web of Science ®Google Scholar
• Benedetti G, Mori M, Panzeri MM, et al. CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. Radiol Med. 2021;126(6):745–760. doi: 10.1007/s11547-021-01333-z
   PubMed Web of Science ®Google Scholar
• Guo C, Zhuge X, Wang Q, et al. The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. Cancer Imaging. 2018;18(1):37. doi: 10.1186/s40644-018-0170-8
   PubMedGoogle Scholar
• Canellas R, Burk KS, Parakh A, et al. Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis. AJR Am J Roentgenol. 2018;210(2):341–346. doi: 10.2214/AJR.17.18417
   PubMed Web of Science ®Google Scholar
• Bian Y, Jiang H, Ma C, et al. CT-Based radiomics score for distinguishing between grade 1 and grade 2 nonfunctioning pancreatic neuroendocrine tumors. Am J Roentgenol. 2020;215(4):852–863. doi: 10.2214/AJR.19.22123
   PubMed Web of Science ®Google Scholar
• Gu D, Hu Y, Ding H, et al. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study. Eur Radiol. 2019;29(12):6880–6890. doi: 10.1007/s00330-019-06176-x
   PubMed Web of Science ®Google Scholar
• Ricci C, Mosconi C, Ingaldi C, et al. The 3-dimensional-computed tomography texture is useful to predict pancreatic neuroendocrine tumor grading. Pancreas. 2021;50(10):1392–1399. doi: 10.1097/MPA.0000000000001927
   PubMed Web of Science ®Google Scholar
• Javed AA, Zhu Z, Kinny-Köster B, et al. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature. Diagn Interv Imaging. 2023;105(1):33–39. doi: 10.1016/j.diii.2023.08.002
   PubMed Web of Science ®Google Scholar
• Liang W, Yang P, Huang R, et al. A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res. 2019;25(2):584–594. doi: 10.1158/1078-0432.CCR-18-1305
   PubMed Web of Science ®Google Scholar
• McGovern JM, Singhi AD, Borhani AA, et al. CT radiogenomic characterization of the alternative lengthening of telomeres phenotype in pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2018;211(5):1020–1025. doi: 10.2214/AJR.17.19490
   PubMed Web of Science ®Google Scholar
• Bodalal Z, Trebeschi S, Nguyen-Kim TDL, et al. Radiogenomics: bridging imaging and genomics. Abdom Radiol. 2019;44(6):1960–1984. doi: 10.1007/s00261-019-02028-w
   PubMed Web of Science ®Google Scholar
• Baumann T, Rottenburger C, Nicolas G, et al. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging. Best Pract Res Clin Endocrinol Metab. 2016;30(1):45–57. doi: 10.1016/j.beem.2016.01.003
   PubMed Web of Science ®Google Scholar
• Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–1601. doi: 10.1007/s00259-017-3728-y
   PubMed Web of Science ®Google Scholar
• Sawicki LM, Deuschl C, Beiderwellen K, et al. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. Eur Radiol. 2017;27(10):4091–4099. doi: 10.1007/s00330-017-4803-2
   PubMed Web of Science ®Google Scholar
• Mapelli P, De Cobelli F, Picchio M. PET/MRI in neuroendocrine tumours: blessings and curses. CRP. 2019;12(2):96–97. doi: 10.2174/1874471012999190404151701
   Google Scholar
• Mapelli P, Ironi G, Fallanca F, et al. 68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. Clin Transl Imaging. 2019;7(5):363–371. doi: 10.1007/s40336-019-00341-4
   Web of Science ®Google Scholar
• Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40(11):1770–1780. doi: 10.1007/s00259-013-2482-z
   PubMed Web of Science ®Google Scholar
• Nicolas GP, Beykan S, Bouterfa H, et al. Safety, biodistribution, and radiation dosimetry of 68 Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study. J Nucl Med. 2018;59(6):909–914. doi: 10.2967/jnumed.117.199737
   PubMed Web of Science ®Google Scholar
• Pauwels E, Cleeren F, Bormans G, et al. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311–331.
   PubMed Web of Science ®Google Scholar
• Johnbeck CB, Knigge U, Loft A, et al. Head-to-head comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451–457. doi: 10.2967/jnumed.116.180430
   PubMed Web of Science ®Google Scholar
• Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59(1):66–74. doi: 10.2967/jnumed.117.202275
   PubMed Web of Science ®Google Scholar
• Subramaniam RM, Bradshaw ML, Lewis K, et al. ACR practice parameter for the performance of gallium-68 DOTATATE PET/CT for neuroendocrine tumors. Clin Nucl Med. 2018;43(12):899–908. doi: 10.1097/RLU.0000000000002309
   PubMed Web of Science ®Google Scholar
• Ambrosini V, Campana D, Polverari G, et al. Prognostic value of 68 Ga-DOTANOC PET/CT SUV max in patients with neuroendocrine tumors of the pancreas. J Nucl Med. 2015;56(12):1843–1848. doi: 10.2967/jnumed.115.162719
   PubMed Web of Science ®Google Scholar
• Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of 68 Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51(3):353–359. doi: 10.2967/jnumed.109.066662
   PubMed Web of Science ®Google Scholar
• Kandathil A, Subramaniam RM. Gastroenteropancreatic neuroendocrine tumor diagnosis: DOTATATE PET/CT. PET Clin. 2023;18(2):189–200. doi: 10.1016/j.cpet.2022.11.001
   PubMed Web of Science ®Google Scholar
• Christ E, Wild D, Forrer F, et al. Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas. J Clin Endocrinol Metab. 2009;94(11):4398–4405. doi: 10.1210/jc.2009-1082
   PubMed Web of Science ®Google Scholar
• Sowa-Staszczak A, Pach D, Mikołajczak R, et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging. 2013;40(4):524–531. doi: 10.1007/s00259-012-2299-1
   PubMed Web of Science ®Google Scholar
• Binderup T, Knigge U, Loft A, et al. 18F-Fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–985. doi: 10.1158/1078-0432.CCR-09-1759
   PubMed Web of Science ®Google Scholar
• Mapelli P, Tam HH, Sharma R, et al. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas. Nucl Med Commun. 2014;35(6):613–619. doi: 10.1097/MNM.0000000000000106
   PubMed Web of Science ®Google Scholar
• Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and therapy management of pancreatic neuroendocrine tumors. Diagnostics. 2020;10(12):1059. doi: 10.3390/diagnostics10121059
   Web of Science ®Google Scholar
• Zhang P, Yu J, Li J, et al. Clinical and prognostic value of PET/CT imaging with combination of 68 Ga-DOTATATE and 18 F-FDG In gastroenteropancreatic neuroendocrine neoplasms. Contrast Media Mol Imaging. 2018;2018:1–9. doi: 10.1155/2018/2340389
   Google Scholar
• Muffatti F, Partelli S, Cirocchi R, et al. Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clin Transl Imaging. 2019;7(3):181–188. doi: 10.1007/s40336-019-00328-1
   Web of Science ®Google Scholar
• Andreasi V, Partelli S, Muffatti F, et al. Update on gastroenteropancreatic neuroendocrine tumors. Digestive Liver Dis. 2021;53(2):171–182. doi: 10.1016/j.dld.2020.08.031
   Web of Science ®Google Scholar
• Matsumoto T, Okabe H, Yamashita Y, et al. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with pancreatic neuroendocrine tumors. Surg Today. 2019;49(1):21–26. doi: 10.1007/s00595-018-1703-2
   PubMed Web of Science ®Google Scholar
• Magi L, Prosperi D, Lamberti G, et al. Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine. 2022;76(2):484–490. doi: 10.1007/s12020-022-03000-3
   PubMed Web of Science ®Google Scholar
• Werner RA, Weich A, Higuchi T, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors - a triple tracer comparative approach. Theranostics. 2017;7(6):1489–1498. doi: 10.7150/thno.18754
   PubMed Web of Science ®Google Scholar
• Bezzi C, Mapelli P, Presotto L, et al. Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance. Eur J Nucl Med Mol Imaging. 2021;48(12):4002–4015. doi: 10.1007/s00259-021-05338-8
   PubMed Web of Science ®Google Scholar
• Ha S, Choi H, Paeng JC, et al. Radiomics in oncological PET/CT: a methodological overview. Nucl Med Mol Imaging. 2019;53(1):14–29. doi: 10.1007/s13139-019-00571-4
   PubMed Web of Science ®Google Scholar
• Mapelli P, Partelli S, Salgarello M, et al. Dual tracer 68Ga-DOTATOC and18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. Nuclear Medicine Communications. 2020;41(9):896–905. doi: 10.1097/MNM.0000000000001236
   PubMed Web of Science ®Google Scholar
• Werner RA, Ilhan H, Lehner S, et al. Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2019;21(3):582–590. doi: 10.1007/s11307-018-1252-5
   PubMed Web of Science ®Google Scholar
• Önner H, Abdülrezzak Ü, Tutuş A. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors? Nucl Med Commun. 2020;41(10):1034–1039. doi: 10.1097/MNM.0000000000001231
   PubMed Web of Science ®Google Scholar
• Mapelli P, Bezzi C, Palumbo D, et al. 68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours. Eur J Nucl Med Mol Imaging. 2022;49(7):2352–2363. doi: 10.1007/s00259-022-05677-0
   PubMed Web of Science ®Google Scholar
• Mapelli P, Partelli S, Salgarello M, et al. Diagnostics dual tracer 68Ga-DOTATOC and 18F-FDG PET improve preoperative evaluation of aggressiveness in resectable pancreatic neuroendocrine neoplasms. Diagnostics. 2021;11(2):192. doi: 10.3390/diagnostics11020192
   Web of Science ®Google Scholar
• Ma J, Wang X, Tang M, et al. Preoperative prediction of pancreatic neuroendocrine tumor grade based on 68Ga-DOTATATE PET/CT. Endocrine. 2023;83(2):502–510. doi: 10.1007/s12020-023-03515-3
   PubMed Web of Science ®Google Scholar
• Mapelli P, Bezzi C, Muffatti F, et al. Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2023;50(9):2818–2829. doi: 10.1007/s00259-023-06210-7
   PubMed Web of Science ®Google Scholar
• Bruckmann NM, Rischpler C, Kirchner J, et al. Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI. Eur J Radiol. 2021;137:109588. doi: 10.1016/j.ejrad.2021.109588
   PubMed Web of Science ®Google Scholar
• Zilli A, Arcidiacono PG, Conte D, et al. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. Digestive Liver Dis. 2018;50(1):6–14. doi: 10.1016/j.dld.2017.10.007
   Web of Science ®Google Scholar
• Anderson M, Carpenter S, Thompson NW. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271–2277. doi: 10.1111/j.1572-0241.2000.02480.x
   PubMed Web of Science ®Google Scholar
• Di Leo M, Poliani L, Rahal D, et al. Pancreatic neuroendocrine tumours: the role of endoscopic ultrasound biopsy in diagnosis and grading based on the WHO 2017 classification. Dig Dis. 2019;37(4):325–333. doi: 10.1159/000499172
   PubMed Web of Science ®Google Scholar
• Partelli S, Muffatti F, Andreasi V, et al. A single-center prospective observational study investigating the accuracy of preoperative diagnostic procedures in the assessment of lymph node metastases in nonfunctioning pancreatic neuroendocrine tumors. Ann Surg. 2022;276(5):921–928. doi: 10.1097/SLA.0000000000005615.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Palazzo L. Endoscopy and endoscopic ultrasound in assessing and managing neuroendocrine neoplasms. Front Horm Res. 2015;44:88–103.
   PubMed Web of Science ®Google Scholar
• Tacelli M, Bina N, Francesco Crinò S, et al. Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data. Gastrointest Endosc. 2022;96(6):898–908.e23. doi: 10.1016/j.gie.2022.07.014
   PubMed Web of Science ®Google Scholar
• Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1–33. doi: 10.1097/MPA.0000000000001454
   PubMed Web of Science ®Google Scholar
• Ishii T, Katanuma A, Toyonaga H, et al. Role of endoscopic ultrasound in the diagnosis of pancreatic neuroendocrine neoplasms. Diagnostics. 2021;11(2):316. doi: 10.3390/diagnostics11020316
   Web of Science ®Google Scholar
• Tacelli M, Petrone M, Capurso G, et al. Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: possible clinical impact of misclassification. Endosc Ultrasound. 2021;10(5):372–380. doi: 10.4103/EUS-D-20-00261
   PubMed Web of Science ®Google Scholar
• Paiella S, Landoni L, Rota R, et al. Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases. Endoscopy. 2020;52(11):988–994. doi: 10.1055/a-1180-8614
   PubMed Web of Science ®Google Scholar
• Hijioka S, Hara K, Mizuno N, et al. Diagnostic performance and factors influencing the accuracy of EUS-FNA of pancreatic neuroendocrine neoplasms. J Gastroenterol. 2016;51(9):923–930. doi: 10.1007/s00535-016-1164-6
   PubMed Web of Science ®Google Scholar
• Leeds JS, Nayar MK, Bekkali NLH, et al. Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. Endosc Int Open. 2019;7(10):E1281–7. doi: 10.1055/a-0990-9611
   PubMed Web of Science ®Google Scholar
• Crinò SF, Ammendola S, Meneghetti A, et al. Comparison between EUS-guided fine-needle aspiration cytology and EUS-guided fine-needle biopsy histology for the evaluation of pancreatic neuroendocrine tumors. Pancreatology. 2021;21(2):443–450. doi: 10.1016/j.pan.2020.12.015.
   PubMed Web of Science ®Google Scholar
• Ghabi EM, Habib JR, Shoucair S, et al. Detecting somatic mutations for well-differentiated pancreatic neuroendocrine tumors in endoscopic ultrasound-guided fine needle aspiration with next-generation sequencing. Ann Surg Oncol. 2023;30(12):7720–7730. doi: 10.1245/s10434-023-13965-8
   PubMed Web of Science ®Google Scholar
• Mastrosimini MG, Manfrin E, Remo A, et al. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors. Pancreatology. 2023;23(4):429–436. doi: 10.1016/j.pan.2023.05.002
   PubMed Web of Science ®Google Scholar
• Vanden Bussche CJ, Allison DB, Graham MK, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. 2017;125(7):544–551. doi: 10.1002/cncy.21857
   PubMed Web of Science ®Google Scholar
• Hackeng WM, Morsink FHM, Moons LMG, et al. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine‐needle aspiration. Diagn Cytopathol. 2020;48(4):308–315. doi: 10.1002/dc.24368
   PubMed Web of Science ®Google Scholar
• Asokkumar R, Yung Ka C, Loh T, et al. Comparison of tissue and molecular yield between fine-needle biopsy (FNB) and fine-needle aspiration (FNA): a randomized study. Endosc Int Open. 2019;7(08):E955–63. doi: 10.1055/a-0903-2565
   PubMedGoogle Scholar
• Yamada M, Hara K, Mizuno N, et al. The role of needle-based confocal laser endoscopy in the diagnosis of pancreatic neuroendocrine tumors. Clin Endosc. 2023. Epub ahead of print.
   Google Scholar
• Iglesias-Garcia J, Larino-Noia J, Abdulkader I, et al. EUS elastography for the characterization of solid pancreatic masses. Gastrointest Endosc. 2009;70(6):1101–1108. doi: 10.1016/j.gie.2009.05.011
   PubMed Web of Science ®Google Scholar
• Kuwahara T, Hara K, Mizuno N, et al. Present status of ultrasound elastography for the diagnosis of pancreatic tumors: review of the literature. J Med Ultrasonics. 2020;47(3):413–420. doi: 10.1007/s10396-020-01026-6
   PubMed Web of Science ®Google Scholar
• Iglesias–Garcia J, Larino–Noia J, Abdulkader I, et al. Quantitative endoscopic ultrasound elastography: an accurate method for the differentiation of solid pancreatic masses. Gastroenterology. 2010;139(4):1172–1180. doi: 10.1053/j.gastro.2010.06.059
   PubMed Web of Science ®Google Scholar
• Giovannini M, Hookey L, Bories E, et al. Endoscopic ultrasound elastography: the first step towards virtual biopsy? Preliminary results in 49 patients. Endoscopy. 2006;38(4):344–348. doi: 10.1055/s-2006-925158
   PubMed Web of Science ®Google Scholar
• Carrara S, Di Leo M, Grizzi F, et al. EUS elastography (strain ratio) and fractal-based quantitative analysis for the diagnosis of solid pancreatic lesions. Gastrointest Endosc. 2018;87(6):1464–1473. doi: 10.1016/j.gie.2017.12.031
   PubMed Web of Science ®Google Scholar
• Havre RF, Ødegaard S, Gilja OH, et al. Characterization of solid focal pancreatic lesions using endoscopic ultrasonography with real-time elastography. Scand J Gastroenterol. 2014;49(6):742–751. doi: 10.3109/00365521.2014.905627
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Itoh A, Kawashima H, et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 2010;71(6):951–959. doi: 10.1016/j.gie.2009.12.023
   PubMed Web of Science ®Google Scholar
• Palazzo M, Napoléon B, Gincul R, et al. Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressivenes. Gastrointestinal Endoscopy. 2018;87(6):1481–1488. doi: 10.1016/j.gie.2017.12.033
   PubMed Web of Science ®Google Scholar
• Ishikawa R, Kamata K, Hara A, et al. Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms. Digestive Endoscopy. 2021;33(5):829–839. doi: 10.1111/den.13862
   PubMed Web of Science ®Google Scholar
• Săftoiu A, Vilmann P, Dietrich CF, et al. Quantitative contrast-enhanced harmonic EUS in differential diagnosis of focal pancreatic masses (with videos). Gastrointest Endosc. 2015;82(1):59–69. doi: 10.1016/j.gie.2014.11.040
   PubMed Web of Science ®Google Scholar
• Takada S, Kato H, Saragai Y, et al. Contrast-enhanced harmonic endoscopic ultrasound using time–intensity curve analysis predicts pathological grade of pancreatic neuroendocrine neoplasm. J Med Ultrasonics. 2019;46(4):449–458. doi: 10.1007/s10396-019-00967-x
   PubMed Web of Science ®Google Scholar
• Constantin AL, Cazacu I, Burtea DE, et al. Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using perfusion parameters? A pilot study. Med Ultrason. 2022;24(4):393. doi: 10.11152/mu-3503
   PubMed Web of Science ®Google Scholar
• Săftoiu A, Vilmann P, Gorunescu F, et al. Neural network analysis of dynamic sequences of EUS elastography used for the differential diagnosis of chronic pancreatitis and pancreatic cancer. Gastrointest Endosc. 2008;68(6):1086–1094. doi: 10.1016/j.gie.2008.04.031
   PubMed Web of Science ®Google Scholar
• Klöppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90(2):162–166. doi: 10.1159/000182196
   PubMed Web of Science ®Google Scholar
• Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–154. doi: 10.1007/s12022-022-09708-2
   PubMed Web of Science ®Google Scholar
• Shi M, Fan Z, Xu J, et al. Gastroenteropancreatic neuroendocrine neoplasms G3: novel insights and unmet needs. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188637. doi: 10.1016/j.bbcan.2021.188637
   PubMed Web of Science ®Google Scholar
• Perren A, Couvelard A, Scoazec J-Y, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology - diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196–200. doi: 10.1159/000457956.
   PubMed Web of Science ®Google Scholar
• Choe J, Kim KW, Kim HJ, et al. What is new in the 2017 World Health Organization classification and 8th American Joint Committee on Cancer staging system for pancreatic neuroendocrine neoplasms? Korean J Radiol Korean Radiological Society. 2019;20(1):5–17. doi: 10.3348/kjr.2018.0040
   PubMed Web of Science ®Google Scholar
• Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNets) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNecs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72(1):168–177. doi: 10.1111/his.13408
   PubMed Web of Science ®Google Scholar
• Maharjan C, Ear P, Tran C, et al. Pancreatic neuroendocrine tumors: molecular mechanisms and therapeutic targets. Cancers (Basel). 2021;13(20):5117. doi: 10.3390/cancers13205117
   PubMed Web of Science ®Google Scholar
• Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71. doi: 10.1038/nature21063
   PubMed Web of Science ®Google Scholar
• Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (1979). 2011;331(6021):1199–1203. doi: 10.1126/science.1200609
   PubMed Web of Science ®Google Scholar
• Marinoni I, Kurrer AS, Vassella E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146(2):453–60.e5. doi: 10.1053/j.gastro.2013.10.020
   PubMed Web of Science ®Google Scholar
• Heaphy CM, Singhi AD. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol. 2022;129:11–20. doi: 10.1016/j.humpath.2022.07.015
   PubMed Web of Science ®Google Scholar
• Hackeng WM, Brosens LAA, Kim JY, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022;71(5):961–973. doi: 10.1136/gutjnl-2020-322595
   PubMed Web of Science ®Google Scholar
• Geurts JL. Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2020;11(3):559–566. doi: 10.21037/jgo.2020.03.09
   PubMed Web of Science ®Google Scholar
• Michael IP, Saghafinia S, Hanahan D A set of microRnas coordinately controls tumorigenesis, invasion, and metastasis. Proc Natl Acad Sci USA. 2019;116(48):24184–24195. doi: 10.1073/pnas.1913307116
   PubMed Web of Science ®Google Scholar
• Havasi A, Sur D, Cainap SS, et al. Current and new challenges in the management of pancreatic neuroendocrine tumors: the role of miRNA-based approaches as new reliable biomarkers. Int J Mol Sci. 2022;23(3):1109. doi: 10.3390/ijms23031109
   PubMed Web of Science ®Google Scholar
• Saller J, White D, Hough B, et al. An miRNA signature predicts grading of pancreatic neuroendocrine neoplasms. Cancer Genomics - Proteomics. 2023;20(2):154–164. doi: 10.21873/cgp.20370
   PubMed Web of Science ®Google Scholar
• Lakis V, Lawlor RT, Newell F, et al. DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Commun Biol. 2021;4(1):155. doi: 10.1038/s42003-020-01469-0
   PubMed Web of Science ®Google Scholar
• Yang KC, Kalloger SE, Aird JJ, et al. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Rep. 2021;37(2):109817. doi: 10.1016/j.celrep.2021.109817
   PubMed Web of Science ®Google Scholar
• Tirosh A, Kebebew E. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2020;11(3):567–577. doi: 10.21037/jgo.2020.03.11
   PubMed Web of Science ®Google Scholar
• Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401. doi: 10.1007/s00428-006-0250-1
   PubMed Web of Science ®Google Scholar
• Boyar Centinkaya R, Vatn M, Aabakken L, et al. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scandinavian Journal Of Gastroenterology. 2014;49(6):734–741. doi: 10.3109/00365521.2014.903432
   PubMed Web of Science ®Google Scholar
• Partelli S, Javed AA, Andreasi V, et al. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. Eur J Surg Oncol. 2018;44(6):778–783. doi: 10.1016/j.ejso.2018.03.005
   PubMed Web of Science ®Google Scholar
• Pomianowska E, Gladhaug IP, Grzyb K, et al. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol. 2010;45(7–8):971–979. doi: 10.3109/00365521003782363
   PubMed Web of Science ®Google Scholar
• Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26(6):803–818. doi: 10.1016/j.bpg.2012.12.004
   PubMed Web of Science ®Google Scholar